^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PD-L1 inhibitor

    Related drugs:
    18h
    ERRα-ETV5 axis drives PD-L1 upregulation and immune escape in gallbladder cancer. (PubMed, Cancer Lett)
    Using a combination of human GBC tissues, in vitro co-culture systems, and a humanized mouse model, we demonstrated that genetic or pharmacological inhibition of ERRα downregulated PD-L1 and potentiated CD8+ T cell-mediated cytotoxicity.​ Critically, combined targeting of ERRα (using the inverse agonist XCT790) and PD-L1 (using durvalumab) synergistically suppressed tumor growth and enhanced intratumoral T cell infiltration in vivo. Our findings reveal ERRα as a master transcriptional regulator of immune evasion and highlight the therapeutic potential of co-inhibiting the ERRα-ETV5-PD-L1 axis to overcome immunotherapy resistance in GBC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • ETV5 (ETS Variant Transcription Factor 5)
    |
    Imfinzi (durvalumab)
    1d
    Pharmacokinetic insights into atezolizumab SC: viability of extended dosing intervals beyond the standard regimen. (PubMed, Clin Transl Oncol)
    Our PopPK model suggests that extending SC atezolizumab dosing to 4 or 5 weeks maintains therapeutic efficacy and could serve as a clinically viable alternative to standard triweekly dosing. Longer intervals may reduce efficacy and require clinical validation.
    PK/PD data • Review • Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
    1d
    SHARP: SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC (clinicaltrials.gov)
    P2, N=66, Recruiting, Fudan University
    New P2 trial
    |
    retlirafusp alfa (SHR-1701)
    2d
    Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Tang-Du Hospital
    New P2 trial
    |
    cisplatin • albumin-bound paclitaxel • AiRuiLi (adebrelimab)
    2d
    An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) (clinicaltrials.gov)
    P2, N=36, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Aug 2026
    Enrollment closed • Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR wild-type • ALK wild-type
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    2d
    Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial (clinicaltrials.gov)
    P2, N=200, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting
    Enrollment closed
    |
    Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    2d
    Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy (clinicaltrials.gov)
    P2, N=13, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    EGFR mutation • ALK mutation
    |
    Imfinzi (durvalumab)
    2d
    Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=110, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date • Tumor mutational burden • IO biomarker
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MSH6 (MutS homolog 6)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    2d
    REFMAL 412: Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=56, Completed, AstraZeneca | Active, not recruiting --> Completed
    Trial completion
    |
    Imfinzi (durvalumab) • adavosertib (AZD1775)
    3d
    A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) (clinicaltrials.gov)
    P1/2, N=129, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • pumitamig (BNT327)
    3d
    Clinical Trial Evaluating TQB6411 Injection in Subjects With Esophageal Cancer (clinicaltrials.gov)
    P1/2, N=105, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open